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Objective: Developing an integrative approach to early treatment response classification
using survival modeling and bioinformatics with various biomarkers for early assessment
of filgrastim (granulocyte colony stimulating factor) treatment effects in amyotrophic lateral
sclerosis (ALS) patients. Filgrastim, a hematopoietic growth factor with excellent safety,
routinely applied in oncology and stem cell mobilization, had shown preliminary efficacy
in ALS.
Methods: We conducted individualized long-term filgrastim treatment in 36 ALS
patients. The PRO-ACT database, with outcome data from 23 international clinical ALS
trials, served as historical control and mathematical reference for survival modeling.
Imaging data as well as cytokine and cellular data from stem cell analysis were
processed as biomarkers in a non-linear principal component analysis (NLPCA) to identify
individual response.
Results: Cox proportional hazard and matched-pair analyses revealed a significant
survival benefit for filgrastim-treated patients over PRO-ACT comparators. We
generated a model for survival estimation based on patients in the PRO-ACT
database and then applied the model to filgrastim-treated patients. Model-identified
filgrastim responders displayed less functional decline and impressively longer
survival than non-responders. Multimodal biomarkers were then analyzed by PCA
in the context of model-defined treatment response, allowing identification of
subsequent treatment response as early as within 3 months of therapy. Strong
treatment response with a median survival of 3.8 years after start of therapy was
associated with younger age, increased hematopoietic stem cell mobilization, less
aggressive inflammatory cytokine plasma profiles, and preserved pattern of fractional
anisotropy as determined by magnetic resonance diffusion tensor imaging (DTI-MRI).
Johannesen et al. Filgrastim in ALS
Conclusion: Long-term filgrastim is safe, is well-tolerated, and has significant
positive effects on disease progression and survival in a small cohort of ALS patients.
Developing and applying a model-based biomarker response classification allows use
of multimodal biomarker patterns in full potential. This can identify strong individual
treatment responders (here: filgrastim) at a very early stage of therapy and may pave
the way to an effective individualized treatment option.
Keywords: amyotrophic lateral sclerosis, granulocyte-colony stimulating factor (G-CSF), filgrastim, biomarker,
modeling, principal component analysis (PCA), cytokines, stem cell
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative
disorder with a median survival time of 15.8 months from
diagnosis (1). Disease etiology and pathophysiology are
multilayered, genetic factors, and inflammation, both systemic
and within CNS, currently receive maximum attention (2).
Filgrastim (granulocyte colony-stimulating factor, G-
CSF) is a safe and widely used FDA-approved drug to
mobilize hematopoietic stem cells. Filgrastim is also a
neuronal growth factor with neuroprotective and regenerative
properties (3, 4), enhancing immunocompetence (5), reducing
neuroinflammation (4), increasing motoneuron functional
activity (4, 6), and improving motor function and survival
in ALS mouse models (4, 7). Since its approval in the early
1990s, filgrastim has been applied in millions of patients and
healthy donors. It is an established and well-tolerated clinical
compound, so far also in some preliminary studies with ALS
patients (4, 8–12).
We provided individual filgrastim treatment to ALS
patients in our ALS-outpatient clinic. Filgrastim was applied
subcutaneously in a cyclic fashion with individually adjusted
dosing. Monthly safety monitoring included assessment of
functional decline and survival, as well as gathering of serum
retain samples. MRI scans were performed every 3 months.
Patient safety and biomarker data from our population have
been analyzed earlier (8–10, 13), because lack of a control group
assessment of potential objective efficacy of filgrastim in ALS was
not possible.
Subsequently, we compared survival and functional decline of
filgrastim-treated ALS patients to the largest publicly available
collection of ALS patient data from international clinical trials,
the PRO-ACT database (Pooled Resource Open-Access ALS
Clinical Trials Database)1. By comparing filgrastim patient data
to PRO-ACT and subgroups of PRO-ACT, we explored and
estimated a potential benefit from filgrastim treatment, both for
disease progression and for survival.
Biomarkers for disease progression and treatment response
are essential in ALS. In view of the heterogeneity concerning
disease etiology, pathophysiology, and clinical phenotype, it
seems unlikely that single biomarkers could provide this
information in total. Rather, an integrated observation of panel
biomarkers within different biological systems over time could
1Available online at: https://nctu.partners.org/ProACT/Data/Index/1nctu.
partners.org
be useful in the understanding of such a complex disease—and
why ALS patients respond so differently to a given treatment. We
generatedmodels for survival prediction to identify ALS patients,
who might benefit most from this new long-term treatment
approach, and assessed development in different biomarker
domains [hematological parameters, stem cells, cytokines, and
structural changes in brain architecture (Magnetic Resonance
Diffusion Tensor Imaging, DTI-MRI)] in responding and non-
responding patients over time. Non-linear principal component
analysis (NLPCA) has been successfully applied in CNS disorders
such as traumatic brain injury (14). NLPCA allows inclusion of
different biomarker domains into one systematic analysis. It is
a robust descriptive tool to reduce the dimensionality of large
numbers of variables, while also handling various data types
(ordinal, scalar, etc.) and missing values. We used this novel and
data-driven approach to a multitude of biomarkers to estimate
treatment effects and individual patients’ prognosis.
METHODS
Description of Filgrastim-Treated Patients
and Intervention
Treatment with subcutaneous filgrastim was offered since
January 2010 to 36 patients with definite or probable sporadic
ALS according to the revised El Escorial criteria (15) after
written informed consent. All patients received standard care and
riluzole 100 mg/day. The ethics committee of the University of
Regensburg approved a retrospective analysis (ethics approval:
15-101-0106 and 14-101-0011). The data were analyzed as of
August 31st, 2017. Individual dosing and application were
defined upon initiation and adapted over time with the
general intention of achieving sufficient hematopoietic stem
cell mobilization to peripheral blood (Supplementary Figure 1,
Table 1) (Further information in Supplementary Material).
Description of PRO-ACT, Statistical
Analysis Plan, and Cohort Comparability
The survival and functional decline control dataset was based
on the latest version of PRO-ACT (release January 2016)1,
containing 10,723 fully de-identified clinical ALS patient records
from 23 phase II/ III trials. The scientific validity of this
dataset has been shown in numerous publications (14, 16–21).
Information on handling of missing data and problematic data
issues is described in the Supplementary Section. We generated
a statistical analysis plan (finalized April 5th, 2018) to explore
and estimate potential benefit in disease progression and survival
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Number of patients 36 708 2,044 1,829
Age (mean) 51.9 years 58.4 years 58.8 years 58.8 years
95% confidence interval 48.4–55.4 57.5–59.3 58.2–59.5 50.0–60.0
Pat. with measurements 36 542 951 1624
ALSFRS-R (mean) 37.6/48 36.9/48 37.0/48 36.7/48
95% confidence interval 35.7–39.5 36.4–37.3 36.6–37.4 36.4–37.0
Pat. with measurements 36 707 825 1513
Latency between onset and treatment 595 days 557 days 576 days 605 days
95% confidence interval 476.7–713.4 530–583.4 551.3–600.8 586.5–622.8
Pat. with measurements 36 707 823 1532
Sex (% female) 30.6% 39.4% 42.8% 40.3%
Onset of symptoms (n) 30/36 limb 425/708 limb 521/2,044 limb 504/1,829 limb
Pat. with measurements 36 (100%) 614 (87%) 699 (34%) 775 (42%)
Percent from “new” studies 100% 79.9% 24.8% 33.5%
Treatment duration (mean) 17.3 months (range
2.7–78.8)
n.a. n.a. n.a.
Treatment response 15/15/6 (yes/no/n.a.) n.a. n.a. n.a.
Survival in months (median) 19.58 13.07 10.12 11.33
95% confidence interval 12.39–35.48 12.39–13.76 9.59–10.48 10.97–11.73
Patients with right-censored survival times 11 266 272 424
ALSFRS-R data were imputed from ALSFRS data if necessary. “New” studies refer to trials that were added in the latest version of PRO-ACT and/or had the revised score ALSFRS-R.
The overall survival dataset (N = 4,617) includes the 36 filgrastim-treated patients and the PRO-ACT survival dataset comprising the three treatment groups. All survival data defined
from start of treatment.
of filgrastim-treated patients in comparison to PRO-ACT. After
testing the robustness of the treatment effects, a model for
survival prediction helped to identify individual response.Within
PRO-ACT, the subgroup of riluzole and placebo-treated patients,
termed “rp-PRO-ACT,” showed the highest survival compared to
all other subgroups and was considered as the best comparator
to filgrastim. The comparability at baseline in the filgrastim-
treated patients and the PRO-ACT database was analyzed by
standard descriptive statistical methods (Further information in
Supplementary Material).
Survival Analyses
Survival analyses were conducted on a final PRO-ACT dataset
of 4,617 patients as defined in the Supplementary Material.
All survival data were defined from start of treatment. For
statistical adjustments, the following variables were considered:
age, sex, ALSFRS-R, site of onset (limb or bulbar), treatment
latency, and riluzole use. “Databases” describes filgrastim or
PRO-ACT groups. In addition to classical proportional hazards
models, the additional accelerated failure time (AFT) analysis
in patient subgroups describes hazard of covariates upon
acceleration/deceleration in the disease course by an event time
ratio (ETR). Further, a matched-pair approach was applied
on PRO-ACT and filgrastim patients (Further information in
Supplementary Material).
Analysis of Functional Decline
The database contained 60,928 ALSFRS-R measurements of
6,599 PRO-ACT and 36 filgrastim patients. Multiple linear
regression models of ALSFRS-R included the following
independent variables: database (filgrastim vs. PRO-ACT
subgroups), time of ALSFRS-R measurement modeled as
three-knot spline, database∗month (representing the interaction
effect), ALSFRS-R score and age at treatment initiation,
treatment latency (onset delta), and sex; the indicator variable
for ALSFRS-R score imputation at baseline (ALS BL Imp
Ind) was included where it had significant influence. The
interaction term “database∗month” quantified the difference in
steepness of ALSFRS-R decline between groups. The analyses
were focused mainly on the first 6 months of treatment. The
estimated mean ALSFRS-R course was compared in patient
subgroups. An extended model, including three-way interactions
(database∗month∗onset delta), tested dependency on treatment
latency (Further information in Supplementary Material).
Models to Estimate Treatment Effect on
Survival Time
To allow estimation of survival times in individual patients,
a general linear model with exponential distribution and
a reciprocal link function was built on deceased rp-PRO-
ACT patients. Variables taken were ALSFRS-R slope (robust
estimate), age, and treatment latency. The model-predicted
individual survival was correlated and compared to the
observed survival within this subgroup. Next, the model
was applied to all PRO-ACT and filgrastim-treated patients
(including censored patients). Subsequently, hypothetical
survival was compared to observed survival. Filgrastim
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treatment response was derived from the difference
between individual model-predicted and observed survival,
a Kaplan–Meyer analysis for both groups was conducted.
To address the question, if ALSFRS-R time courses differ
dependent on filgrastim response, treatment response
was added in the mixed-effect model for estimation of
functional decline.
Biomarker Signature for Individualized
Treatment Response
We assessed cytokines at baseline and 3, 6, 9, and 12 months by
multiplex electrochemiluminescence. Hematological parameters
were assessed at the same timepoints. CD34+ and CD34+CD38−
hematopoietic stem and progenitor cells (HSPC) were analyzed
in peripheral blood by flow cytometry as previously described
A B
C
FIGURE 1 | Survival analyses. (A) Unadjusted survival analysis comparing filgrastim with PRO-ACT groups. Kaplan–Meier survival plot with shaded pointwise 95% CIs,
by study group. Green: filgrastim group; turquoise: rp-PRO-ACT group (riluzole- and placebo-treated PRO-ACT); black: riluzole, no placebo-treated PRO-ACT; blue:
PRO-ACT group not treated with riluzole/or not known treatment. All data defined from start of treatment. (B) AFT model for survival analysis. Density plot of predicted
survival times from the accelerated failure time (AFT) model in rp-PRO-ACT subgroup (blue) and filgrastim (green). Survival times are given by the time to event. The
HR for PRO-ACT patients over filgrastim patients was 3.5, the event-time ratio for filgrastim was 0.55. (C) Model scheme of the matching plus bootstrapping
approach in matched-pair analysis. For the matching with bootstrapping approach, the matching algorithm was first tested in a reduced number of 10 draws and by
comparison of age and ALSFRS-R in the filgrastim patients and their 10 matching rp-PRO-ACT patients. Adequate matching was challenged by visual proof and test
for equivalence (TOST). Survival comparison: From the 10 respective rp-PRO-ACT matching counterparts of each filgrastim patient, 9 were randomly included to a
survival analysis together with the filgrastim patients, and survival curves were analyzed by the YP model by Yang and Zhou (22) (Supplementary Material).
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(10). Structural MRI was conducted at two 1.5-Tesla scanners.
We used the model-generated filgrastim response groups and
evaluated blood cytokines by an area under the curve (AUC)
approach. We used the baseline value of the analyzed biomarker
as bottom border and a line connecting the measured values at 3,
6, and 9 months as upper border.
Several biomarkers with a multitude of dimensionality were
detected in filgrastim treated patients over time. Non-linear
principal component analyses were applied in the evaluation of
hematological parameters, stem cells, cytokines, and structural
changes in brain architecture (diffusion tensor imaging, DTI-
MRI) as a robust descriptive tool to reduce the dimensionality of
large numbers of variables, handling various data types (ordinal,
scalar, etc.) and missing values (14). A non-linear principal
component analysis (NLPCA) was used to determine covariance
among variables within each biomarker package. NLPCA was
performed for each biomarker package separately at three time
points: all available measures up to 3months, up to 6months, and
up to 12 months. The goal of these analyses is to (1) determine
which variables at each time point aremost highly correlated with
the variance explained by a particular principal component, (2)
identify the emergent “identity” of each principal component,
and (3) use the normalized principal component scores (PC
scores) to run specific hypothesis tests of group differences. This
approach allowed us to reduce a large number of variables into a
single composite outcome score for each PC and then perform a
single hypothesis test, rather than runmultiple tests on individual
outcome measures, increasing our probability of committing a
Type I error. For the following analyses, only those variables
that were over an absolute loading threshold of 0.5 are shown;
this thresholding step allows domain experts to focus only on
those variables that are most strongly correlated with the variance
explained by their respective PCs, in order to best identify
the identity of that PC. The statistical significance level for all
analyses was set to α = 0.05. Data for DTI–ROI determinations,
cell mobilization, and hematology were treated accordingly.
A linear mixed model was conducted, with the previously
determined responder categories serving as independent
variables (Further information in Supplementary Material).
RESULTS
Patient Cohorts
Thirty six sporadic ALS patients (25 male, 28 limb onset,
eight bulbar onset) received filgrastim in addition to riluzole
(Table 1). Mean age at treatment initiation was 51.9 years,
mean latency between symptom onset and treatment initiation
was 595 days, and mean ALSFRS-R was 37.6/48. Dose and
application modes were individualized, and detailed description
may be seen in Supplementary Figure 1. The mean dose of
480 Mio IU/month (range 90 to 2,160 Mio IU/month) was
applied subcutaneously, mainly as 5-day treatment block once
or twice a month, or continuously on single days (mostly every
second day). The median duration of treatment was 13.8 months
(mean 17.3 months; range from 2.7 to 78.8 months). Filgrastim
was well tolerated, and safe, minor adverse events were mild
to moderate bone pain after injections, and—as expected—
leukocytosis. One patient developed a possible drug-related
intolerance or mild allergic reaction after 39 months of filgrastim
treatment (Supplementary Figure 1). Baseline characteristics in
comparison to PRO-ACT are provided in detail in Table 1.
Adjustments are detailed in Supplementary Material.
Survival and Progression
The filgrastim group showed a significant median survival benefit
(19.6 months, 95% CI 12.4–35.5) from the first year onward
compared to all PRO-ACT patients (11.1 months, 95% CI 10.7–
11.3, p < 0.0001 by log-rank test) and the subgroup of rp-PRO-
ACT patients (13.1 months, 95% CI 12.4–13.8, p = 0.0029 by
log-rank test; overall test between all groups: p< 0.0001, log-rank
and Wilcoxon test; Figure 1A, Table 1).
In 1,544 PRO-ACT and filgrastim patients, age, sex, baseline
ALSFRS-R, site of onset, treatment latency, and riluzole use were
used as covariates for adjusted parametric survival analyses.
Contributions of all covariates were significant, except for riluzole
use. The Cox proportional-hazard ratio for all PRO-ACT patients
over filgrastim was 2.44 and 0.41, respectively (p < 0.0001,
Supplementary Figure 2); for rp-PRO-ACT patients (n = 499),
the Cox proportional-hazard ratio was 1.93 and 0.52, respectively
(p = 0.0052; Table 2). The estimated significant survival benefit
was smaller in male patients, in bulbar onset, in higher age,
in lower baseline ALSFRS-R, and in longer treatment latency.
In the AFT model, an HR of 2.2 and an ETR 0.63 were
obtained by comparing the filgrastim cohort to rp-PRO-ACT
patients (increase in median survival by 1.6-fold) (Figure 1B).
In a “Matched Pairs” approach (Figure 1C), the estimated mean
survival in filgrastim-treated patients was significantly longer
(596 days), compared to the PRO-ACT-matched patients (373
days; survival given as mean of the medians in all 100,000 draws;
all p < 0.001 by YP test; Supplementary Figure 3). Comparison
TABLE 2 | Adjusted Cox proportional hazard fit and parametric survival analyses
with available riluzole- and placebo-treated PRO-ACT patients.
Variable Cox PH model Parametric model
Wald test Wald test
Wald chi p-value Wald chi p-value
square square
ALSFRS-R at baseline 44.88 <0.001 43.07 <0.001
Age 41.24 <0.001 47.87 <0.001
Database 7.80 0.0052 13.09 0.0003
Sex 5.59 0.0180 6.64 0.0100
Treatment latency 5.24 0.0220 4.77 0.0289
Site of onset 9.52 0.0231 9.99 0.0186
Statistical significance of survival contribution of a factor is given by its p-value. The
significant term “Database” refers to filgrastim or rp-PRO-ACT (riluzole- and placebo-
treated PRO-ACT) patients and indicates treatment effect. Number of events 395; number
of censorings 140; total number 535. AIC (4,214.85) and BIC (4,248.83) indicate the
Akaike and Bayesian information criterion, respectively. “ALSFRS-R at baseline” indicates
ALSFRS-R at first visit and was imputed from ALSFRS where necessary. “Treatment
latency” gives the latency in days between onset of disease and treatment start.
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of filgrastim (596 days) with the matched patients from the rp-
PRO-ACT subgroup again revealed a significant difference with
survival at 403 days in this group (median p-value of 0.005, range
of p-values: 0.0001 to 0.07, by YP test; Supplementary Figure 3).
Mixed effect modeling of ALSFRS-R functional decline over
6 months was compared in filgrastim- and riluzole-treated
PRO-ACT patients (6,927 measurements). The interaction
term database∗month (p < 0.0001) indicates a treatment
difference in functional decline evolving linearly over time
(Supplementary Figure 4). Using a more complex three-way
interaction term model, we found an inverse relation between
the estimated difference in ALSFRS-R scores between filgrastim
and PRO-ACT groups, and treatment latency. In patients with
treatment latency of 10 months, the model-estimated difference
between filgrastim and patients from new PRO-ACT studies
differed by 3.7 ALSFRS-R score points in favor of filgrastim (p =
0.0002, interaction term; Figure 2A, Supplementary Figure 6).
Individual data points and smoothing splines also visualized
the ALSFRS-R scores up to 6 and 36 months in both groups
(Figures 2B,C, Supplementary Figure 5).
Models to Estimate Individual Patient
Treatment Effects
We build a general linear model for individual patient survival
prediction on influential patient variables (calculated ALSFRS-
R slope, age, and treatment latency) derived from 447 deceased
patients in the rp-PRO-ACT subgroup. The resulting model-
predicted patient survival correlated with the observed survival
within this subgroup (p < 0.0001) with a difference near
zero. This remained when applying the model to all PRO-ACT
patients. The difference between observed and model-predicted
survival was significantly greater in filgrastim patients than in
FIGURE 2 | Analysis of clinical progression. (A) Estimated ALSFRS-R courses. The interaction profile of estimated ALSFRS-R score time courses of filgrastim- (green,
N = 36) and riluzole-treated PRO-ACT patients from new studies only (blue, N = 6,927) with treatment latency of 10 months includes measurements up to 6 months.
The model-estimated decline in filgrastim-treated patients was flatter (interaction term p = 0.0002), and the estimated difference between filgrastim and PRO-ACT
after 6 months was 3.7 ALSFRS-R score points. (B,C) Visualization of individual ALSFRS-R data points over 36 months. Individual ALSFRS-R scores (dots) over 36
months. (B) (blue): N = 6,927 riluzole receiving PRO-ACT patients, (C) (green): N = 36 filgrastim-treated patients. Individual data points and smoothing splines
visualized the ALSFRS-R scores with 95% CIs. Filgrastim patients stabilize at around 28 ALSFRS-R points; however, already here 2 populations are recognizable.
PRO-ACT patients stabilize at around 17 ALSFRS-R points.
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all PRO-ACT patients and in the rp-PRO-ACT subgroup (p <
0.001, Wilcoxon test, Figure 3A). A Waterfall plot illustrates the
distribution of patients with longer (“responders” = 15) over
shorter (“non-responders” = 15) than model-predicted survival
in individual filgrastim-treated patients (Figure 3B). Patients
with negligible difference were classified as “non-assignable” (n
= 6, Figure 3C). Model-identified responders had a significant
survival benefit over non-responders with 1,378 vs. 337.5 days
median survival after start of treatment (p < 0.0001, log-rank
test; Figure 4A). This was reflected by slowing of functional
decline, when adapting the mixed effect model and replacing the
database variable by responder group (Supplementary Figure 7)
in slope analysis. An increasing difference in functional decline—
depending on individual filgrastim response—was revealed
by the significant interaction term month∗responder group (p
< 0.0001, Figure 4B) and the plotted individual ALSFRS-R
data points (Figure 4C). As age was found to be a strong
covariate in survival, the parametric survival model, extended
by the interaction term database∗age, confirmed this dependency
between age and treatment (Supplementary Figure 8). When
correlating model-predicted survival times with patient age in
the context of database (filgrastim vs. PRO-ACT), as well as in
context of filgrastim response (responder vs. non-responder),
a strong association of filgrastim-induced survival response
with age was evidenced (Figure 4D): younger patients up
to 60 years obviously had a much higher chance for this




FIGURE 3 | Modeling for survival estimation. (A) Model for survival estimation. A general linear model for individual patient survival prediction based on patient
variables (calculated ALSFRS-R slope, age, and treatment latency) was built in 447 deceased rp-PRO-ACT subgroup patients. The resulting model-predicted patient
survival correlated with the observed survival within this subgroup (p < 0.0001; first, turquoise graph). This observation remained identical when applying the model to
all PRO-ACT patients (blue graph). The observed survival in filgrastim patients (green graph) was significantly longer than in all PRO-ACT patients and in rp-PRO-ACT
subgroup (p < 0.001, Wilcoxon test). (B) Difference between observed and model-predicted survival. The differences between observed and model-predicted survival
in individual filgrastim patients are given by individual dots. Turquoise dots: responders (n = 15); pink dots: non-responder (n = 15); white dots: non-assignable
patients (n = 6). (C) Waterfall plot for difference between observed to model-predicted survival. Waterfall plot illustration of the difference between observed and
model-predicted survival in filgrastim patients (green lines, N = 36) and PRO-ACT patients (blue lines, N = 6,927), where positive values indicate longer than predicted
individual survival. **p < 0.001.
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FIGURE 4 | Modeling to identify individual patient response. (A) Kaplan–Meier plots of responding and non-responding patients from Figure 3B. Kaplan–Meier
survival plot of responding (turquoise, N = 15) and non-responding (pink, N = 15) filgrastim patients with shaded pointwise 95% CIs. Model-identified responders had
a significant survival benefit over non-responders with 1,378 vs. 337.5 days median survival (p < 0.0001, log-rank test). (B) Estimated ALSFRS-R courses in different
filgrastim response groups. Interaction profile of estimated ALSFRS-R score time courses in the different filgrastim response groups with responding patients given by
turquoise color, non-responding by pink, and non-assignable patients indicated by black color. A slowing of functional decline is impressive in responders. An
increasing difference in functional decline—depending on individual filgrastim response—was revealed by the significant interaction term month*responder group (p <
0.0001). (C) ALSFRS-R scores over time in different filgrastim response groups. ALSFRS-R scores over time in individual filgrastim-treated patients with responding
patients given by turquoise color, non-responding by pink, and non-assignable patients by white color. The interaction term from (B) is valid here too. (D) Individual
model-predicted survival times depending on age. The individual predicted patient survival (dots) dependent on age is illustrated in filgrastim (green) and rp-PRO-ACT
patients (blue, both in first graph), and within filgrastim-treated patients (responding: turquoise, non-responding: pink, and non-assignable patients: white color; all
second graph). The smooth curves of the second graph represent the model-predicted survival times (y-axis), dependent on age (x-axis). The first graph indicates that
especially younger ALS patients benefit from filgrastim treatment but that a treatment benefit might be expected up to ∼60 years of age. The second graph illustrates
the filgrastim response groups and supports this assumption but also shows that the filgrastim-responding group contains patients up to ∼70 years of age; the
response assessment of these patients can only be fully understood as additional covariates beyond age have been taken into account.
Biomarker Signature for Individualized
Treatment Response
We then clustered patients by treatment response (15 patients
in each group) to analyze peripheral cytokines by an area under
the curve (AUC) approach. Assessing timepoints at 3, 6, and 9
months of treatment revealed significantly higher serum levels
of IL 6, MCP 1, eotaxin, and MCP 4, as well as TNF beta and
IL 7 as a trend, in non-responding patients (Figure 5). We then
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FIGURE 5 | Cytokine levels in filgrastim response groups. Differences in serum cytokine levels between responding (Turquoise) and non-responding patients (Pink; N
= 15 in each group) were assessed by area under the curve (AUC) over the first 9 months of filgrastim treatment (IL 6 p = 0.05, MCP 1 p = 0.05, eotaxin p = 0.002,
TNF-beta p = 0.09, MCP 4 p = 0.05, IL 7 p = 0.07). Initial values obtained before first filgrastim treatment were used as baseline for the AUC calculation. Shown are
only items with p < 0.1.
assessed biomarker signatures in the treatment response groups
by principal component (PC) analysis. After normalization for
dimensionality, biomarkers from 36 filgrastim patients contained
immune-biomarkers, hematology pre- and post-mobilization
parameters, and follow-up data on 48 ROIs from DTI-based
1.5-Tesla MRI datasets (Figure 6). We selected the respective
PC accounting for the highest percent of variance between
patients within each biomarker package (imaging, hematology,
and cytokines) at 3, 6, and 12 months of treatment (Figure 7,
Supplementary Figures 9, 10). The correlation between each
item (variable, e.g., specific cytokine) and the variance explained
within this PC was determined as “loading” of that specific
cytokine and used for ranking: only variables with an absolute
loading threshold of >0.5 were included in the subsequent
analysis. To assess the predictive validity of the biomarker
packages, we compared individual patient scores on the selected
PCs with response to filgrastim. Subsequently, we prepared a
meta-PC analysis of only the significant PCs from individual
clusters (Figure 8). For this, each patient was associated with
a specific response PC score. This sensitivity/specificity analysis
was executed by receiver operating characteristics (ROC) curves
and applied separately at all given timepoints.
We first investigated the neuroimaging data at 12 months.
PC3 was driven mainly by areas from motor system and
neurogenesis and accounts for 9.5% of variance. Responding
patients had significantly higher PC3 scores, indicative of
more sustainedmotor system/neurogenesis than non-responders
(p < 0.01; Figure 7). Hematology PC3 was driven by stem
cell mobilization and monocytes (15.3% of the variance).
Responders had significantly higher PC3 scores than non-
responders (p < 0.01; Figure 7). In cytokine PC1, consisting
mainly of inflammatory markers (23.9% of the variance),
responding patients had a significantly higher loading (p <
0.01; Figure 7). From these significant PCs at 12 months, a
meta-PC was generated, discriminating between responding
and non-responding patients, with responders exhibiting higher
scores (p < 0.01; Figure 8). ROC analysis confirmed the
meta-PC at 1 year to be a significant predictor of patient
response to treatment [area under the curve (AUC) = 0.854,
p < 0.01].
Imaging data could not be analyzed at 6 and 3 months due
to missing data. At 6 months of treatment, again hematology
(PC1, 24.7% of the variance, p < 0.01) and stem cell
markers (PC3, 12.9% of the variance, p < 0.019) as well
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FIGURE 6 | Non-selected PCA at 12 months of filgrastim treatment. Unselected non-linear principal component analyses (PCA) of neuroimaging data [(A), first heat
plot: fractional anisotropy (FA) in cerebral MRI DTI], cytokines and growth factors [(B), second heat plot], and hematology parameters [(C), third heat plot] at 12
months of filgrastim treatment. For single items (e.g., specific cytokine), the loading is given in absolute numbers and used for ranking; red color indicates positive
magnitude of loading, blue negative magnitude of loading.
as markers for inflammatory cytokines (PC1, 39.1% of the
variance, and PC3, 14.4% of the variance, both p < 0.01)
explained the variance in responding and non-responding
patients (Supplementary Figure 10). This resulted in a more
complex meta-PC, with responders exhibiting higher scores (p
< 0.01; Figure 8). The corresponding ROC analysis confirms
that the meta-PC at 6 months was modestly predictive of
treatment response (AUC = 0.633, p = 0.023; Figure 8). At
3 months (Supplementary Figure 9), responders had higher
scores in hematology PC3 (stem cells and monocytes, 13.6%
of the variance, p < 0.01). For cytokines, two significant PCs
separated the patient groups: responders had lower scores in
PC1 (microvascular/macrophage, 25.8% of the variance) and
higher scores in PC3 (T-cell/macrophage response, 15.5% of
the variance) (both p < 0.01). The meta-PC was significantly
predictive (ROC analysis) of treatment response (AUC = 0.677,
p = 0.026; Figure 8). Consequently, a significant prediction of
response was possible after only 3 months of treatment.
DISCUSSION
We retrospectively analyzed a novel therapeutic approach in ALS
with long-term filgrastim application in 36 patients. We chose
the well-known PRO-ACT database for reference and modeling.
The treatment of a small number of ALS patients and the use
of historical controls are obvious limitations one has to keep
in mind when generalizing our results. To ensure comparability
at baseline, we characterized the cohorts of filgrastim-treated
and PRO-ACT patients, addressed the main outcome covariates,
and adjusted for baseline difference whenever necessary. The
comparability was quite adequate; however, filgrastim patients
were on average 6 years younger than PRO-ACT patients, which
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FIGURE 7 | Selected PCA at 12 months of filgrastim treatment. Focusing upon selected non-linear PCA of neuroimaging (neurogenesis and motor response; first
part), cytokines (T-cell and macrophage response; second), and hematology (stem cell mobilization; last part) at 12 months of treatment. The PC compounds
explaining most of the variance were selected, and only items loading over a threshold of >0.5 were included to the analysis: PC3 reflecting motor system and
neurogenesis was chosen for the imaging evaluation (p < 0.01); PC1 was selected for the cytokine data—reflecting the T-lymphocyte-macrophage response (p <
0.01); in hematology PC3 was selected, reflecting stem cell mobilization and monocyte mobilization (p < 0.01). The graphs give a comparison of scores on the
selected PCs in responding vs. non-responding filgrastim patients. PCAs at 3 and 6 months are displayed in Supplementary Material.
was compensated for whenever needed (Table 1). The riluzole-
and placebo-treated patients (rp-PRO-ACT) were the best-
performing PRO-ACT cohort (Figure 1A) and most suitable
comparators. The Cox proportional-hazard model gave a 0.52
hazard ratio for death in filgrastim vs. rp-PRO-ACT patients
(Table 2). Matched-pair analysis (Supplementary Figure 3) and
the AFT model (Figure 1B) confirmed this effect level in
filgrastim therapy. This was clinically mirrored by analysis
of ALSFRS-R progression at six (Supplementary Figure 4)
and 36 months (Supplementary Figure 5). Interestingly, effects
become more pronounced with shorter treatment latency
(Supplementary Figure 6) and longer treatment duration—both
to be expected in a CNS repair strategy.
A main achievement by our statistical approach was
the generation of a model for survival estimation that
was based on deceased patients in the PRO-ACT database.
When this survival model was applied to filgrastim-treated
patients, it classified them as responders or non-responders
due to individual differences between model-estimated and
observed survival time (Figure 3). The clinical relevance of the
model-identified response classification was mirrored by less
functional decline and impressively longer survival in filgrastim-
responding patients (Figures 4A–C). In a next step, multimodal
biomarkers were analyzed in the context of model-identified
treatment response. This allowed an early and biomarker-
driven identification of subsequent individual patient’s treatment
response. Here, treatment response was explicitly associated with
early bioinformatic PCA patterns of multimodal structural, stem
cell, and immune biomarkers: filgrastim responders mobilized
stem cells more efficiently, had less inflammatory reaction,
and showed relatively preserved cerebral white matter integrity
(Figures 6–8). Altogether, this procedure not only shed light
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FIGURE 8 | Individual patient response. Comparison of individual patient response by meta-PCs and testing of ROC (sensitivity/specificity) at 3, 6, and 12 months.
We generated meta-PCs from the significant PCs at 3, 6, and 12 months of filgrastim treatment and analyzed the relationship between the meta-PCs and individual
treatment response. Responding and non-responding patients have significantly different mean meta-PC scores at all timepoints, with patients responding better to
treatment exhibiting higher scores (LMM, all p < 0.01). The receiver operating characteristic (ROC) curves showed that the meta-PCs were significantly predictive of
whether patients would have responded to treatment or not (at 3 months: AUC = 0.677, p = 0.026; at 6 months: AUC = 0.633, p = 0.023; at 1 year: AUC = 0.854,
p < 0.01). Although there is already quite a good prediction at 3 months, this will be much more accurate at 12 months. *p < 0.005.
on possible modes of action of filgrastim in ALS but may also
pave the methodological way for other therapeutic options in
ALS patients.
As we did not perform genetic testing, lack of information
on genetic background is a limitation when analyzing the data.
We found that younger filgrastim patients responded better
to treatment; however, on top of their age-related prognostic
advantage, they survived considerably longer than their age-
matched PRO-ACT counterparts (Supplementary Figure 8,
Figure 4D). With filgrastim, an age-dependent benefit is
plausible. Direct CNS effects as well as indirect effects
mediated by hematopoietic stem cells have been described
(4). Both CNS and the hematopoietic system suffer from age-
dependent decline of regenerative capacities. Elderly individuals
mobilize hematopoietic stem cells less efficiently (23) and
exhibit an elevated inflammatory response (24). In stem cell
transplantation, younger age is the only donor factor associated
with longer receiver survival (25). A 60-year limit is accepted
in filgrastim mobilization for stem cell harvesting2. However,
our model revealed that also some elderly filgrastim patients
lived longer than predicted—the individual stem cell age and
2Available online at: https://bethematch.org/transplant-basics/matching-patients-
with-donors/why-donor-age-matters/
immune functions seem to be crucial, as shown in a recent paper
(9). Being aware of our non-randomized experimental setting
and small patient number, our data are the first to show that
drug-mobilized autologous stem cells have a significant impact
on performance and survival in a neurodegenerative disorder
like ALS (19).
Filgrastim may exert beneficial effects in ALS by multiple
possible mechanisms of action. It is a neuronal growth factor
within the CNS that exerts neuroprotective properties (3, 4) and
induces neurogenesis (3, 8, 26). Specifically, neuroinflammation
is increasingly recognized in ALS pathogenesis (2), and immune
modulating effects by filgrastim may establish a more protective
immune status (27). Filgrastim mobilizes hematopoietic stem
cells that may migrate to the CNS and may offer trophic support
and immune modulation within the CNS (28, 29). Therefore, the
responding and non-responding ALS patients were characterized
by peripheral cytokines. Patients responding to treatment had
indeed lower levels of inflammatory cytokines over the first 9
months of treatment (Figure 5).
The impact of a biomarker-guided individualized ALS
therapy was highlighted by modeling. We addressed the
complexity of individual ALS patients by modeling the
different pathophysiologic impacts of inflammation, stem
cells, and brain structure, as well as biomarker response to
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treatment, in a comprehensive way, not paralleled before
in ALS. We thereby detected approximately 40% of strong
filgrastim responders. We need to keep in mind that in other
patient populations response rates may be higher or lower,
depending on individual compositions, treatment latency, and
duration. Indeed, biomarker evaluation allowed assignment of
patient response to filgrastim as early as within 3 months
of treatment. Thus, treatment time windows for response
known from oncology may also apply for neurodegeneration;
this strongly highlights the imperative necessity of early
therapeutic intervention.
Filgrastim is a widely used, well-tolerated drug, with an
excellent safety profile in ALS that has been highlighted by
Wallner et al. (4) and our group (9). Minor adverse events were
mild to moderate bone pain and—as expected—leukocytosis
after injection.We found that filgrastim-treated patients survived
longer than PRO-ACT patients on a group level, but also
longer than individually predicted by modeling. This further
supports filgrastim as a safe therapeutic option in ALS. Earlier
filgrastim studies in ALS patients have displayed positive
effects on inflammation and neuroimaging (11, 12), but the
promising survival data from animal models have not yet
been translated to patients. In comparison to earlier studies
in ALS patients (4), our positive outcome may have been
achieved by higher doses of filgrastim, in part shorter treatment
latencies, more frequent applications, and by far more extended
treatment duration.
In this diligent and in-depth comparison of survival and
functional decline in filgrastim-treated patients, we considered
all PRO-ACT patients as reference and then narrowed the
comparison down to the most suitable cohort of rp-PRO-
ACT patients, which was also used for further modeling.
We paid particular attention to relevant methodical bias,
made adjustments for demographic and clinical differences
between the two groups, and conducted analysis in carefully
matched patients. Comparable results in different statistical
approaches confirmed the stability of the difference in functional
decline and survival between filgrastim and PRO-ACT. We
developed a PRO-ACT-based model for individual survival
prediction and applied this model to filgrastim patients
to detect treatment response. Individuals most responsive
to treatment were then identified at the early stage by
principal component biomarker analysis for stem cells,
neuroinflammation, and structural imaging. Although the
treatment effect is impressively associated with age—young
patients benefited most from treatment—also some of the
elder patients were clearly treatment responders. Subcutaneous
filgrastim has a favorable safety profile: thus, the benefit risk
ratio is positive, as our data give a clear signal of efficacy with
both slower clinical progression and increased survival in
ALS patients.
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Supplementary Figure 1 | Illustration of individual filgrastim treatment evolving
over time. ALS patients were seen at the outpatient clinic once or twice á month
with assessment of clinical status and laboratory work-up. Further, once to twice á
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month hematopoietic stem cells were assessed in peripheral blood and blood
samples were stored for later evaluation of cytokines and chemokines. The
duration of individual filgrastim treatment is given by the framed area, the color
intensity indicates the mean monthly filgrastim dose, which is also specified in Mio
IU/month. The gray bars show survival after filgrastim treatment was ended, “>”
gives time of death, and “I” the end of data entry. Filgrastim application modes
were adapted over time. Filgrastim was mainly given either in intervals (A–D) or
continuously on single days [(E–G), and “other”]. (A) Filgrastim once or twice á
day over 5 following days á month. (B) as in “A” with repetition of interval once á
month (i.e., 2 × 5 days). (C) as in “B” with additional application every second day
between intervals. (D) Three days of application á month. (E) Application once or
twice á day on a single day á week. (F) Application every second day. [(G) and
“other”]: different combinations of applications on single days á week. Filgrastim
treatment was terminated in patient number 21. After 39 months of application he
experienced an episode of heat sensation, lightheadedness, and 15min of
dyspnea. As drug-related intolerance or mild allergic reaction could not be
excluded, filgrastim was ended in this patient. Antibodies against filgrastim were
not detected. This patient was switched to PEGylated G-CSF (Pegfilgrastim 6mg)
from his 46th to 53rd month of treatment and then ended the treatment without
further adverse reactions.
Supplementary Figure 2 | Adjusted Cox Proportional Hazards fit and parametric
survival analyses with all available PRO-ACT patients. Significance of survival
contribution of a factor is given by it’s p-value. The significant term “database”
refers to filgrastim or PRO-ACT and indicates treatment effect. Number of events
1,280; number of censorings 264; total number 1,544. The model predicted
adjusted increase in median survival time under filgrastim compared to PRO-ACT
was 11.4 months (p < 0.0001) while the increase in model predicted median
survival time under riluzole (yes vs. no) was about 0.7 months only (p = 0.5351).
Supplementary Figure 3 | Matched pairs, YP-model. Significant survival
differences are given by p-values from 10,000 repeats of matching each filgrastim
patient to 10 PRO-ACT patients that were selected from both all PRO-ACT
patients (first graph) as well as only patients from the rp-PRO-ACT subgroup
(second graph) by YP-model. Mean survival in filgrastim treated patients was
significantly longer (596 days), compared to the PRO-ACT matched patients (373
days; survival given as mean of the medians in all 100,000 draws; all p < 0.001 by
YP test). Comparison of filgrastim (596 days) with the matched patients from the
rp-PRO-ACT subgroup revealed a significant difference with survival at 403 days in
this group (median p-value of 0.005, range of p-values: 0.0001–0.07, by YP test).
Supplementary Figure 4 | Table of all fixed effect variables included into the
mixed effect model for estimation of ALSFRS-R decline over the first 6 months.
“Database” refers to the two groups of filgrastim treated vs. PRO-ACT patients
treated with riluzole. The significant interaction term “database∗month” indicates a
different steepness in functional decline depending on treatment group. The effect
variables are sorted by increasing p-value (last column).
Supplementary Figure 5 | Visualization of individual ALSFRS-R data points over
6 months. Individual ALSFRS-R scores (dots) over the first 6 months: first graph
(green): N = 36 filgrastim treated patients, second graph (blue): N = 6,927 riluzole
receiving PRO-ACT patients. Individual data points and smoothing splines
visualized the ALSFRS-R scores with 95%-CIs.
Supplementary Figure 6 | Table of all fixed effect variables included into the
mixed effect model for estimation of ALSFRS-R decline over the first 6 months in
patients with treatment latency shorter than 10 months. “Database” refers to the
two groups of filgrastim treated vs. all PRO-ACT patients from only newer studies.
The significant interaction term “database∗month” indicates a different steepness
in functional decline depending on treatment group. The effect variables are sorted
by increasing p-value (last column).
Supplementary Figure 7 | Table of all fixed effect variables included into the
mixed effect model for estimation of ALSFRS-R. “Responder group” refers to the
two groups of filgrastim treated, who have a longer or shorter survival than
model-estimated. The significant interaction term “month∗responder group”
indicates a different steepness in functional decline depending on treatment
group. The effect variables are sorted by increasing p-value (last column).
Supplementary Figure 8 | Parametric survival model with interaction term. The
contributing factors to the model for survival estimation are given. The model was
extended by the interaction term database∗age. This interaction term captures a
possible dependency between database (i.e., filgrastim or rp-PRO-ACT) and age.
Supplementary Figure 9 | Selected PCA at 3 months. Selected non-linear PCA
of cytokines (T-cell and macrophage response, (A) microvascular and
macrophage response, (B) and stem cell mobilization (C) at 3 months of
treatment. The PC compounds explaining most of the variance were selected, and
only items loading over a threshold of >0.5 were included to the analysis. The
graphs give a comparison of scores on the selected PCs in responding vs.
non-responding filgrastim patients.
Supplementary Figure 10 | Selected PCA at six months. Selected non-linear
PCA of cytokines (T-cell and macrophage response (A), Killer-cell and
macrophage response (B), stem cell mobilization (C), as well as hematopoietic
response (D) at 6 months of treatment. The PC compounds explaining most of
the variance were selected, and only items loading over a threshold of >0.5 were
included to the analysis. The graphs give a comparison of scores on the selected
PCs in responding versus non-responding filgrastim patients.
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